ALX Oncology Announces Upcoming Virtual Investor Conference Participation
November 02 2021 - 9:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., Founder, President and Chief Executive Officer and other
senior executives, will participate in four upcoming virtual
investor conferences.
Credit Suisse 30th
Annual Healthcare ConferenceFormat: Fireside chat
with analyst, Tiago FauthDate: Monday, November 8Time: 2:40 PM
Eastern TimeWebcast link: Available here
Stifel 2021 Healthcare ConferenceFormat:
Fireside chat with analyst, Bradley CaninoDate: Tuesday, November
16 Time: 10:00 AM Eastern TimeWebcast link: Available here
Jefferies 2021 London Healthcare Conference
Format: Fireside chat with analyst, Michael YeeDate: Thursday,
November 18 – Friday, November 19Webcast link: Available here
Piper Sandler
33rd Virtual
Healthcare ConferenceFormat: Fireside chat with analyst,
Christopher RaymondDate: Monday, November 22 Time: 10:00 AM Eastern
TimeWebcast link: Will be made available shortly
A webcast of the fireside chats can be accessed
by visiting the Investors section of ALX Oncology’s website at
www.alxoncology.com and selecting Events under the News and Events
tab. A replay of the webcasts will be archived for up to 90 days
following the fireside chat dates.
About ALX Oncology
ALX Oncology is a publicly traded,
clinical-stage immuno-oncology company focused on helping patients
fight cancer by developing therapies that block the CD47 checkpoint
pathway and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept (also known as
ALX148), is a next-generation CD47 blocking therapeutic that
combines a high-affinity CD47 binding domain with an inactivated,
proprietary Fc domain. Evorpacept has demonstrated promising
clinical responses across a range of hematologic and solid
malignancies in combination with a number of leading anti-cancer
agents. ALX Oncology intends to continue clinical development of
evorpacept for the treatment of multiple solid tumor indications
and hematologic malignances, including acute myeloid leukemia and
myelodysplastic syndromes.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Aug 2024 to Sep 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Sep 2023 to Sep 2024